Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.93 | 1.95 |
NAV | ₹36.33 | ₹394.60 |
Fund Started | 12 Nov 2018 | 04 Jun 1999 |
Fund Size | ₹2950.74 Cr | ₹3312.89 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 12.27% | 18.38% |
3 Year | 18.88% | 21.68% |
5 Year | 27.17% | 28.19% |
1 Year
3 Year
5 Year
Equity | 97.59% | 97.28% |
Cash | 2.41% | 2.63% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Suven Pharmaceuticals Ltd. | 10.25% |
Sun Pharmaceutical Industries Ltd. | 10.13% |
Cipla Ltd. | 8.54% |
Ipca Laboratories Ltd. | 7.37% |
Globus Medical Inc | 6.39% |
Gland Pharma Ltd. | 4.84% |
Illumina Inc. (USA) | 4.22% |
Apollo Hospitals Enterprise Ltd. | 4.00% |
Laurus Labs Ltd. | 3.96% |
Sai Life Sciences Ltd. | 3.73% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.47% |
Max Healthcare Institute Ltd. | 6.50% |
Divi's Laboratories Ltd. | 6.20% |
Cipla Ltd. | 5.10% |
Lonza Group Ag | 5.00% |
Lupin Ltd. | 4.83% |
Mankind Pharma Ltd. | 3.87% |
Aether Industries Ltd. | 3.61% |
Jupiter Life Line Hospitals Ltd. | 3.47% |
Poly Medicure Ltd. | 3.32% |
Name | Jay Kothari | Tanmaya Desai |
Start Date | 16 Mar 2018 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 12 Nov 2018 | 04 Jun 1999 |
Description
Launch Date